3D Medicines focuses on next-generation immuno-oncology – 3D Medicines

简繁EN
Antengene

Company Introduction

3D Medicines Inc. is a commercialization stage bio-pharmaceutical company, focused on the field of cancer treatment. With a mission to help people with cancer live longer and better, we commit to developing a new generation of therapies for cancer patients around the world, following a future when cancer is managed as a chronic disease. Our differentiated or world-leading portfolio of 12 drug candidates with clinical benefit includes eight in clinical or commercialization stage. Our global first subcutaneously-injectable PD-L1 antibody Envafolimab co-developed by partner has submitted BLA in China. The global first-in-class peptide cancer vaccine 3D189 and GAS6 decoy protein 3D229 are in an ongoing global Phase III trial. Our in-house developed multi-target kinase inhibitor 3D011 has also entered clinical development. We currently have a strong international team of R&D, manufacture and commercialization members. 

MORE

April 2021

04
04
04
04
04
04
04
March 2020
October 2020
November 2020
December 2020
January 2021
March 2021
April 2021

PipelineThe company has established a multi-core collaborative clinical pipeline

Candidate Molecule

Target/
Mechanism

Rights

Preclinical

IND

Phase I

Phase II

Phase Ⅲ

NDA

Partner

Candidate
Molecule

Target/
Mechanism

Rights

Preclinical

IND

Phase I

Phase Ⅱ

Phase Ⅲ

NDA

Partner

  • Envafolimab
  • PD-L1
  • Worldwide

  • MSI-H/dMMR advanced cancer (mono, 2L+, ORR, tissue agnostic indication)

  • BTC (combo with chemo vs. chemo, randomized, OS, 1L)

  • Sarcoma (mono, +ipilimumab, ORR, 2L+)

  • NSCLC (combo, 1L)

  • NSCLC (combo, 2L+)

  • Urothelial cancer (mono vs. BSC, 1L maintenance)

  • TMB-H advanced cancer (2L+ mono)

  • Endometrial cancer (combo with lenvatinib, 2L+)

  • HCC (combo with VEGF inhibitor, 2L+)

  • Renal cell carcinoma (combo with VEGF inhibitor, 1L/ 2L+)

  • Multiple indications

  • Alphamab Group
    Simcere Group
    TRACON

MORE

  • 3D189
  • WT1
  • Great China

  • Multiple indications

  • AML/MPM/OC/MM

  • SELLAS Group

MORE

  • 3D229
  • GAS6/AXL
  • Great China

  • NSCLC/OC/RCC/UC

  • OC/RCC/UC

  • Aravive

MORE

  • 3D1001
  • COX-2
  • China

  • Post-surgical dental pain/cancer pain

  • Haihe Biopharma Group

MORE

  • 3D1002
  • EP-4
  • China

  • Cancer pain / osteoarthritis

  • Haihe Biopharma Group

MORE

  • 3D185
  • FGFR1/2/3
  • Worldwide

  • Solid tumors / BTC / UC

  • Haihe Biopharma Group & SIMM

MORE

  • 3D011
  • TKI prodrug
  • Worldwide

  • HCC / RCC / PC

MORE

  • 3D197
  • CD47
  • Great China

  • Multiple indications

  • Multiple indications

  • ImmuneOncia

MORE

  • 3D057
  • CD3+PD-L1
  • Greater China + Worldwide Priority Transfer right

  • Multiple indications

  • Y-Biologics

MORE

  • 3D059
  • WT1
  • Greater China

  • Multiple indications

  • SELLAS Group

MORE

  • 3D060
  • Sema4D
  • Worldwide

  • Multiple indications

MORE

  • 3D062
  • KRAS
  • Worldwide

  • Multiple indications

MORE

Pipeline

  1. Envafolimab
  2. 3D189
  3. 3D229
  4. 3D1001
  5. 3D1002
  6. 3D185
  7. 3D011
  8. 3D197
  9. 3D057
  10. 3D059
  11. 3D060
  12. 3D062

CEO MESSAGE

"With the increasing incidence of cancer, cancer has become one of the major public health problems facing mankind; it not only poses a major threat to human health, but also causes a serious burden to economic and social development.

With commitment to the R&D and commercialization of a next-generation of innovative immuno-oncology drugs, 3D Medicines hopes to provide cancer patients across the globe with more effective, more accessible, and more convenient options of next-generation immuno-oncology drugs, thus helping them to live longer and better."


-- John Gong, M.D., Ph.D., Chairman and CEO of 3D Medicines Inc.

MORE

Company News

MORE

Copyright © 3D Medicines Inc. All Rights Reserved